Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on September 25, 2020, by Axsome Therapeutics, Inc. (Nasdaq: AXSM), a biopharmaceutical company. The filing discloses the entry into a material definitive agreement involving a new credit facility and the termination of a prior loan agreement.
Key Financial Metrics and Transaction Details
The Company entered into a Loan and Security Agreement with Hercules Capital, Inc. and other lenders for term loans totaling up to $225.0 million across five tranches.
- Initial Funding: $50.0 million funded on the Closing Date (September 25, 2020), with an additional $10.0 million available at the Company's option through September 15, 2021.
- Debt Retirement: Approximately $21.5 million of the initial proceeds was used to fully retire the Company's previous indebtedness under a credit facility with Silicon Valley Bank and West River Innovation Lending Fund VIII, LP.
- Interest Rate: The greater of the prime rate plus 5.90% or 9.15%. The Company has the option to defer up to 1.00% of the cash interest as paid-in-kind (PIK) interest during specific periods.
- Repayment Terms: Principal and interest payments commence on May 1, 2023, with a maturity date of October 1, 2025. Amortization start dates may be extended based on the achievement of regulatory milestones for product candidates AXS-05 and AXS-07.
- Equity Component: The Company issued a warrant to Hercules to purchase 15,541 shares of common stock (representing 2.5% of the initial funded amount) at an exercise price of $80.43 per share, exercisable for seven years.
Material Changes Versus Prior Period
The primary material change is the replacement of the Company's previous credit facility with the new Hercules Capital facility. The filing does not provide comparative revenue, profit, or cash flow metrics for the period, as this is a transactional filing rather than a periodic financial report.
Outlook, Risks, and Contingencies
Future Funding Contingencies: Additional tranches totaling up to $175.0 million are contingent upon specific milestones:
- Tranche 2 ($35.0 million): Contingent on FDA approval of AXS-05 for major depressive disorder.
- Tranche 3 ($20.0 million): Contingent on FDA approval of AXS-07 for migraine.
- Tranche 4 ($60.0 million): Contingent on achieving either milestone and maintaining a required ratio of lender indebtedness to net product revenue.
- Tranche 5 ($50.0 million): Subject to lender discretion.
Risks and Covenants: The agreement includes customary covenants limiting additional indebtedness, liens, and asset sales. It contains a negative pledge on intellectual property, including a license agreement with Antecip Bioventures II LLC. Events of default include non-payment, insolvency, and material adverse effects. Prepayment penalties range from 1.0% to 2.0% depending on the timing of prepayment.
Key Facts for Investor Verification
- Verify the current status of the $10.0 million optional drawdown available through September 15, 2021.
- Monitor clinical trial progress and regulatory approval timelines for AXS-05 and AXS-07 to assess the likelihood of accessing the $55.0 million in milestone-based tranches.
- Review the Company's cash burn rate to determine the necessity of drawing down future tranches or refinancing before the 2023 amortization start date.
- Confirm the impact of the warrant issuance on potential future dilution, noting the $80.43 exercise price.
- Check subsequent filings for the full text of the Loan Agreement and Direct Agreement to review detailed covenant language.